"J147 enhances memory in both normal and Alzheimer's mice and also protects the brain from the loss of synaptic connections," says David Schubert, the head of Salk's Cellular Neurobiology Laboratory, whose team developed the new drug. "No drugs on the market for Alzheimer's have both of these properties."
Monday, December 26, 2011
Salk scientists develop new drug that improves memory and prevents brain damage in mice
Saturday, November 24, 2012
CLR01 effectively inhibits synaptotoxicity in mice with Alzheimer's
"This is the first demonstration that molecular tweezers work in a mammalian animal model," said Gal Bitan, an associate professor of neurology at UCLA and the senior author of the study. "Importantly, no signs of toxicity were observed in the treated mice. The efficacy and toxicity results support the mechanism of this molecular tweezer and suggest these are promising compounds for developing disease-modifying therapies for Alzheimer's disease, Parkinson's and other disorders."
Wednesday, November 5, 2014
Walnuts may help prevent Alzheimer's disease, study finds
Tuesday, January 5, 2016
Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients
Thursday, January 28, 2021
Alzheimer's disease drug may help fight against antibiotic resistance
In continuation of my update on PBT2
Researchers from The University of Queensland, The University of Melbourne and Griffith University have discovered that the drug called PBT2 is effective at disrupting and killing a class of bacteria -- known as Gram-negative bacteria -- that cause infections such as pneumonia, bloodstream infections and meningitis.
UQ's Professor Mark Walker said the metal transport drug may offer a last line of defence against some of the world's most difficult to treat superbugs.
"The emergence of antibiotic-resistant superbugs is an urgent threat to human health, undermining the capacity to treat patients with serious infection," Professor Walker said.
"Alternative strategies to treat such multi-drug resistant bacteria are urgently needed.
"Led by UQ's Dr David De Oliveira, our team hypothesised that, by using this experimental Alzheimer's treatment to disrupt the metals inside these bacteria, we would also disrupt their mechanisms of antibiotic resistance.
"This was shown to be the case, with the Alzheimer's drug -- combined with the antibiotic polymyxin -- successfully tackling antibiotic-resistant superbugs like Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli."
Griffith University's Professor Mark von Itzstein AO from the Institute for Glycomics said the new treatment was effective, and offered a range of other benefits.
"Based on its use as an experimental Alzheimer's treatment, there's been a significant amount of solid science done on this drug already," Professor von Itzstein said.
"We know, for example, that clinical studies of PBT2 show that it is safe for use in humans.
"And, given that we've been able to combine it with the antibiotic polymyxin to treat polymyxin-resistant bacteria, we may be able to make other now-ineffective antibiotics become effective again for treating infectious diseases.
"This could resharpen, so to speak, some of the weapons we thought we'd lost in our fight against antibiotic-resistant bacteria."
The University of Melbourne's Associate Professor Christopher McDevitt, from the Peter Doherty Institute for Infection and Immunity (Doherty Institute), said the drug had already proved effective beyond the petri dish.
"Animal studies show that the combination of polymyxin and PBT2 kills polymyxin-resistant bacteria, completely clearing any infection," Associate Professor McDevitt said.
"Hopefully in the not-too-distant future people will be able to access this type of treatment in the clinic.
"New techniques are critical in addressing this building threat to human health, and this treatment is an additional weapon in our arsenal to fight the accelerating threat of antibiotic resistance.
"If these new solutions aren't developed, it's estimated that by 2050, antimicrobial-resistant bacteria will account for more than 10 million deaths per year.
"This new treatment could help turn the tide on antibiotic resistance."
https://en.wikipedia.org/wiki/PBT2
Thursday, December 28, 2017
Benzodiazepines linked to increased risk of death among Alzheimer’s disease patients
Tuesday, May 26, 2015
Viagra can have anti-cancer, anti-Alzheimer's disease effects if used with new drugs
Tuesday, August 20, 2013
Scientists ID compounds that target amyloid fibrils in Alzheimer's, other brain diseases
Monday, February 16, 2015
'Mad Cow' discovery points to possible neuron killing mechanism behind alzheimer’s and parkinson’s diseases
Monday, March 19, 2012
New RAGE inhibitor shows promise against Alzheimer's
New RAGE inhibitor shows promise against Alzheimer's: Researchers have taken another crack at a promising approach to stopping Alzheimer's disease that encountered a major hurdle last year. In research published this week in the Journal of Clinical Investigation, scientists have developed a compound that targets a molecular actor known as RAGE (Receptor for Advanced Glycation End Products), which plays a central role in mucking up the brain tissue of people with the disease.
Wednesday, June 24, 2020
Suvorexant May Improve Insomnia With Alzheimer Disease
"Suvorexant did not appear to impair next-day cognitive or psychomotor performance as assessed by objective tests, although these assessments do not constitute a comprehensive assessment of cognition," the authors write.
Friday, April 21, 2017
Metallic molecule offers real-time monitoring of amyloid plaques in patients with Alzheimer's
"Our hypothesis is that upon ultraviolet irradiation, our (rhenium) metal complex produces reactive oxygen species and they're more aggressive than conventional molecular oxygen," Aliyan said. "There are reports that rhenium complexes are capable of activating oxygen from one form to a more aggressive form in solution."
"That's one of our theories," Martí added. "We still don't understand well what is happening. But we know that besides increasing the emission intensity, the complex also chemically modifies the (amyloid) protein."
"We've always been interested in knowing where these complexes bind," he said. "If they oxidize amyloid beta in the periphery of their binding site, then by tracking the place of oxidation we will know the place of binding. That is called footprinting. It will allow us to specifically explore binding and how chemical modification of the surface of the protein would affect factors like toxicity and aggregation."
Friday, November 30, 2012
Diabetes drug rosiglitazone, improves memory, study suggests
"Using this drug appears to restore the neuronal signaling required for proper cognitive function," said UTMB professor Larry Denner, the lead author of a paper describing this work now online in the Journal of Neuroscience. "It gives us an opportunity to test several FDA-approved drugs to normalize insulin resistance in Alzheimer's patients and possibly also enhance memory, and it also gives us a remarkable tool to use in animal models to understand the molecular mechanisms that underlie cognitive issues in Alzheimer's."
Sunday, March 25, 2012
Paclitaxel drug slows damage and symptoms in (Alzheimer's disease) animal model
Potential Alzheimer's disease drug slows damage and symptoms in animal model
Monday, October 8, 2012
Potential drug for treatement of Alzheimer's disease investigated
Potential drug for treatement of Alzheimer's disease investigated
Monday, June 18, 2012
Scientists Discover Drug Candidate for Alzheimer’s, Huntington’s
In mice modeling Alzheimer's disease, the novel compound prevented memory deficits and the loss of synaptic connections between brain cells—both of which are key features of the human disease. In mice modeling Huntington's disease, JM6 prevented brain inflammation and the loss of synaptic connections between brain cells, while also extending lifespan.
“This discovery has significant implications for two devastating diseases and suggests that the KMO enzyme is a good protein for us to target with medications in diverse neurodegenerative disorders,” said Lennart Mucke, MD, who oversees all neurological research at Gladstone and who won the prestigious Potamkin Prize last year for developing experimental strategies to make the brain more resistant to Alzheimer's. “With any luck, Dr. Muchowski and his colleagues could begin testing this drug in patients within the next two years.”
JM6 was named for Dr. Muchowski's father, Dr. Joseph Muchowski, PhD, a retired medicinal chemist who helped his son devise the novel KMO inhibitor. The study was carried out in collaboration with the laboratories of Dr. Robert Schwarcz, a University of Maryland School of Medicine professor who pioneered studies linking KMO and metabolically related enzymes to nerve-cell loss, and Professor Eliezer Masliah at the University of California, San Diego, an expert in neuropathology.
Ref : www.cell.com/abstract/S0092-8674(11)00581-2
Thursday, October 24, 2013
Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease
Monday, February 23, 2009
Phenylbutyrate for treating Alzheimer's Disease !...
Alzheimer's disease is a neurodegenerative disorder associated with age and characterized by the progressive deterioration of cognitive and intellectual abilities. "Cognitive deficit is associated with a loss of neuron connections. For the memory to develop, it is necessary for a series of cellular and molecular mechanisms to be activated. The interruption of these processes affects the capacity to assimilate and store new memories. Since this a drug already established for its toxicity, if the results claimed by Dr. Ana are established and the mechanism of action are studied, hope this research will add one more drug as serendipity and also the much needed help for those sufferings...